Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.

Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.